Tarsus Pharmaceuticals, Inc. Quarterly Debt-to-equity in % from Q2 2021 to Q3 2024

Taxonomy & unit
ratio: %
Description
Debt-to-equity (D/E) ratio is used to evaluate a company's financial leverage and is calculated by dividing a company's total liabilities by its shareholder equity.
Summary
Tarsus Pharmaceuticals, Inc. quarterly Debt-to-equity history and growth rate from Q2 2021 to Q3 2024.
  • Tarsus Pharmaceuticals, Inc. Debt-to-equity for the quarter ending September 30, 2024 was 42.2 %, a 82.1% increase year-over-year.
Debt-to-equity, Quarterly (%)
Debt-to-equity, YoY Quarterly Growth (%)
Period Value YoY Chg Change % Date
Q3 2024 42.2 +19 +82.1% Sep 30, 2024
Q2 2024 34.3 +13.7 +66.3% Jun 30, 2024
Q1 2024 28.6 +11.2 +63.9% Mar 31, 2024
Q4 2023 27.6 +10.4 +59.9% Dec 31, 2023
Q3 2023 23.2 +8.36 +56.4% Sep 30, 2023
Q2 2023 20.6 +8.48 +69.8% Jun 30, 2023
Q1 2023 17.5 +7.75 +79.9% Mar 31, 2023
Q4 2022 17.3 +11 +176% Dec 31, 2022
Q3 2022 14.8 +9.41 +174% Sep 30, 2022
Q2 2022 12.2 +5.55 +84.2% Jun 30, 2022
Q1 2022 9.7 Mar 31, 2022
Q4 2021 6.26 Dec 31, 2021
Q3 2021 5.41 Sep 30, 2021
Q2 2021 6.59 Jun 30, 2021
* An asterisk sign (*) next to the value indicates that the value is likely invalid.